Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

LON­DON — With near­ly a fifth of to­tal sales com­ing from Chi­na, As­traZeneca counts the coro­n­avirus-hit na­tion as one of its biggest growth dri­vers. The im­pact of the dead­ly epi­dem­ic has un­sur­pris­ing­ly weighed on the British drug­mak­er’s fourth-quar­ter re­sults.

On Fri­day, As­traZeneca post­ed fourth-quar­ter sales of $6.25 bil­lion, just shy of Wall Street es­ti­mates. Near­ly $1.2 bil­lion of that prod­uct rev­enue came from Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER